in

PolarityTE Stock Drops On FDA Clinical Hold On SkinTE Trial Application

PolarityTE Stock Drops On FDA Clinical Hold On SkinTE Trial Application

  • The FDA has issued a clinical hold on PolarityTE Inc's (NASDAQ: PTE) SkinTE Investigational New Drug Application (IND) for chronic cutaneous ulcers.
  • The FDA provided feedback on certain Chemistry, Manufacturing, and Control (CMC) items that need to be addressed …

Full story available on Benzinga.com